Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment
NCT ID: NCT02077868
Last Updated: 2019-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
540 participants
INTERVENTIONAL
2014-09-30
2020-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma
NCT01208194
Genotyping of Metastatic Colorectal Cancer Patients for Precision Medicine Clinical Trials
NCT03350412
Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients
NCT01453257
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
NCT03531632
Axitinib as Maintenance Treatment in Patients With Metastatic CRC
NCT01483638
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
MGN1703 is developed not only to help the Patient to recover from chemotherapy but also to boost the patient's immune System and thus help him to effectively fight the Tumor himself.
After the concept has already been proved in a previous study this Trial is conducted to further evaluate the safety and efficacy of MGN1703 Treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Arm A
Patients in Control Arm A receive usual maintenance Treatment according to local investigator's decsision
Usual Maintenance
Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
Treatment Arm B
MGN1703 treatment as maintenance therapy
MGN1703 treatment
MGN1703 will be used as single agent maintenance treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Usual Maintenance
Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
MGN1703 treatment
MGN1703 will be used as single agent maintenance treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female patient 18 years or older
* Histologically confirmed diagnosis of colorectal cancer presenting with unresectable stage IV (UICC) disease (primary tumor may be present)
* Complete or partial response, as assessed by local investigators according to RECIST 1.1, within 12-30 weeks from start of induction treatment with standard first-line chemotherapy with or without biological agents
* ECOG PS 0-1
* Haematology and biochemistry laboratory results within the limits normally expected for the patient population recovering after receiving induction treatment
* Male and female patients of childbearing potential (i.e. did not undergo surgical sterilization - hysterectomy, bilateral tubal ligation, or bilateral oophorectomy - and are not post-menopausal for at least 24 consecutive months) must use an effective method of contraception. Females of child bearing potential must have a negative serum pregnancy test
Exclusion Criteria
* Known brain metastases (present or treated)
* Contraindication to receiving MGN1703 as per current investigator brochure
* Known hypersensitivity to any component of the study product
* Prior allogeneic stem cell transplantation or organ transplantation
* Active or uncontrolled infections or undiagnosed febrile condition
* Severe anemia requiring repeated blood cell transfusion
* Pre-existing autoimmune or antibody-mediated diseases or immune deficiency
* Chronic systemic immune therapy or immunosuppressant medication other than steroids within the last 6 weeks; continuous systemic steroid treatment within the last 2 weeks prior to start of study treatment
* Use of systemic antibiotic therapy within the last 2 weeks prior to start of study treatment
* Inadequate pulmonary function according to the Investigator's judgment, history of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan
* HIV seropositivity or active HBV/HCV infection
* Serious concomitant disease or medical condition that in the judgment of the investigator renders the patient at high risk of treatment complications
* Female patient who is pregnant or breast feeding
* Contraindication to receive the planned standard maintenance treatment according to applicable SmPC
* Treatment with any anti-cancer investigational drug within 12 months prior to study treatment or participation in another clinical study with other investigational drugs within 28 days prior to study treatment
* Vaccination within 1 months prior to start of study treatment
* Any medical, mental, psychological or psychiatric condition that in the opinion of the investigator would not permit the patient to complete the study or understand the patient information
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mologen AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Cunningham, MD
Role: PRINCIPAL_INVESTIGATOR
Royal Marsden Hospital London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Landesklinikum Krems
Krems, , Austria
Kaiser-Franz-Josef-Spital
Vienna, , Austria
Krankenhaus Hietzing
Vienna, , Austria
Universitätsklinik Wien
Vienna, , Austria
Onze-Lieve-Vrouwziekenhuis VZW (OLV)
Aalst, , Belgium
Antwerp University Hospital
Edegem, , Belgium
UZ Leuven
Leuven, , Belgium
East-Tallinn Central Hospital
Tallinn, , Estonia
North Estonia Medical Centre
Tallinn, , Estonia
University clinic Tartu
Tartu, , Estonia
Hôpital Jean Minjoz
Besançon, , France
Institut Bergonié
Bordeaux, , France
CHRU Brest - Hôpital Morvan
Brest, , France
Hôpital Henri Mondor
Créteil, , France
Polyclinique du Bois
La Chaussée-Saint-Victor, , France
Centre Hospitalier Départemental Vendée
La Roche-sur-Yon, , France
Clinique Victor Hugo
Le Mans, , France
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez
Lille, , France
CHU Hôpital de la Timone
Marseille, , France
Centre Hospitalier Belfort-Montbéliard
Montbéliard, , France
Hôpital Antoine-Béclère
Paris, , France
Groupe Hosptalier Paris Saint Joseph
Paris, , France
Institut Mutualiste Montsouris
Paris, , France
Hôpital Européen Georges Pompidou (HEGP)
Paris, , France
Hopital Pitie-Salpetriere
Paris, , France
Gustave Roussy Cancer Campus
Paris, , France
CHU de Poitiers
Poitiers, , France
Centre Eugene Marquis
Rennes, , France
Centre Hospitalier Privé Saint-Grégoire
Saint-Grégoire, , France
Clinique Saint Anne, Strasbourg Oncologie Liberale
Strasbourg, , France
Hôpital Rangueil
Toulouse, , France
Klinikum Augsburg
Augsburg, , Germany
Zentralklinik Bad Berka GmbH
Bad Berka, , Germany
Internistische Schwerpunktpraxis
Bad Reichenhall, , Germany
Klinikum Mittelbaden Baden-Baden Balg
Baden-Baden, , Germany
Klinikum Mittelbaden Medizinische Klinik II
Baden-Baden, , Germany
Klinikum Bayreuth GmbH
Bayreuth, , Germany
Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin
Berlin, , Germany
Medizinisches Versorgungszentrum Ärzteforum Seestrasse
Berlin, , Germany
Ärzteforum Hennigsdorf
Berlin, , Germany
St. Josef-Hospital im Katholischen Klinikum Bochum
Bochum, , Germany
Onkologie / Hämatologie
Bottrop, , Germany
Überörtliche Gemeinschaftspraxis
Bottrop, , Germany
DIAKO Ev. Diakonie-Krankenhaus gemeinnützige GmbH
Bremen, , Germany
Universitätsklinikum Köln
Cologne, , Germany
Gefos Dortmund MBM
Dortmund, , Germany
Onkozentrum Dresden/Freiberg
Dresden, , Germany
Unversitätsklinikum Carl Gustav Carus
Dresden, , Germany
Kliniken Essen-Mitte
Essen, , Germany
Frankfurter Diakonie Kliniken
Frankfurt, , Germany
Universitätsklinikum Frankfurt
Frankfurt, , Germany
Klinik für Tumorbiologie
Freiburg im Breisgau, , Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, , Germany
Medizinisches Versorgungszentrum Osthessen GmbH
Fulda, , Germany
Universitätsklinikum Gießen und Marburg, Standort Gießen
Giessen, , Germany
MVZ Onkologische Kooperation Harz
Goslar, , Germany
Onkologische Schwerpunktpraxis
Gütersloh, , Germany
Universitätsklinikum Halle (Saale)
Halle, , Germany
Facharztzentrum Eppendorf
Hamburg, , Germany
Medizinische Hochschule Hannover
Hanover, , Germany
Onkologische Schwerpunktpraxis Leer-Emden
Leer, , Germany
Klinikum Leverkusen
Leverkusen, , Germany
Onkologie Dreiländerdreieck
Loerrach, , Germany
Onkologie Dreiländereck - Onkologische Schwerpunktpraxis Lörrach
Loerrach, , Germany
Klinikum Ludwigsburg
Ludwigsburg, , Germany
Universitaetsmedizin der Johannes-Gutenberg-Universitaet
Mainz, , Germany
Klinikum Mannheim GmbH
Mannheim, , Germany
University Hospital Marburg
Marburg, , Germany
Kliniken Maria Hilf GmbH
Mönchengladbach, , Germany
Klinikum Bogenhausen
München, , Germany
Klinikum Neuperlach
München, , Germany
Klinikum rechts der Isar
München, , Germany
Klinikum Nürnberg
Nuremberg, , Germany
Pius-Hospital Oldenburg
Oldenburg, , Germany
Klinikum Oldenburg
Oldenburg, , Germany
Sana Kliniken Ostholstein
Oldenburg, , Germany
Paracelsus-Krankenhaus Ruit
Ostfildern, , Germany
St. Vincenz-Krankenhaus
Paderborn, , Germany
Oncologianova GmbH
Recklinghausen, , Germany
Elblandkliniken
Riesa, , Germany
Vivantes Klinikum
Spandau, , Germany
Klinikum Stuttgart - Katharinenhospital
Stuttgard, , Germany
Kliniken Südostbayern
Traunstein, , Germany
Universitätsklinikum Tübingen
Tübingen, , Germany
Universitätsklinikum Ulm
Ulm, , Germany
Universitätsklinikum Ulm
Ulm, , Germany
Horst Schmidt Klinik
Wiesbaden, , Germany
Marienhospital
Witten, , Germany
HELIOS Klinikum Wuppertal Medizinische Klinik I
Wuppertal, , Germany
Candiolo Cancer Institute
Candiolo, , Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, , Italy
University Hospital San Martino
Genova, , Italy
Ospedale San Raffaele
Milan, , Italy
Istituto Oncologico Veneto
Padua, , Italy
Policlinico San Mateo
Pavia, , Italy
Ospedale Infermi di Rimini, U.O. Oncologia
Rimini, , Italy
Ospedale Civile SS Annunziata, U.O.C. Oncologia Medica
Sassari, , Italy
Azienda Ospedaliero-Universitaria Santa Maria della Misericordia
Udine, , Italy
Complexo Hospitalario Universitario A Coruña
A Coruña, , Spain
Hospital Clinic
Barcelona, , Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Hospital Universitari Germans Trias i Pujol
Barcelona, , Spain
Hospital Universitario Vall d'Hebron
Barcelona, , Spain
Parc Tauli Sabadell Hospital
Barcelona, , Spain
Hospital Reina Sofía
Córdoba, , Spain
Hospital de la Santa Creu i Sant Pau
L'Hospitalet de Llobregat, , Spain
Hospital Universitario Arnau de Vilanova
Lleida, , Spain
Hospital Clínico San Carlos
Madrid, , Spain
Hospital General Universitario Gregorio Marañón
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario Puerta de Hierro - Majadahonda
Madrid, , Spain
Hospital Universitario Ramon y Cajal
Madrid, , Spain
Hospital Regional Universitario Carlos Haya
Málaga, , Spain
Hospital Universitario Central de Asturias
Oviedo, , Spain
Hospital Son Llatzer
Palma de Mallorca, , Spain
Hospital Universitario 12 de Octubre
Santander, , Spain
Complejo Hospitalario Universitario
Santiago de Compostela, , Spain
Consorcio Hospital General de Valencia
Valencia, , Spain
Aberdeen Royal Infirmary
Aberdeen, , United Kingdom
The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust - Royal Bournemouth Hospital
Bournemouth, , United Kingdom
Royal Marsden Hospital
London, , United Kingdom
The Christie Clinic
Manchester, , United Kingdom
Oxford University Hospitals NHS Trust - Churchill Hospital
Oxford, , United Kingdom
Royal Marsden Hospital
Sutton, , United Kingdom
York Teaching Hospitals NHS Fondation Trust, Research and Development department
York, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MGN1703-C06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.